NielsenSTKrogh MadsenRMøllerK. Glucose metabolism in critically ill patients: are incretins an important player?J Intensive Care Med. 2015;30(4):201–208.
2.
ElrickHStimmlerLHladCJJrAraiY. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082.
3.
McIntyreNHoldsworthCDTurnerDS. New interpretation of oral glucose tolerance. Lancet. 1964;2(7349):20–21.
4.
DeaneAChapmanMJFraserRJHorowitzM. Bench-to-bedside review: the gut as an endocrine organ in the critically ill. Crit Care. 2010;14(5):228.
5.
MeierJJNauckMA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?Diabetes. 2010;59(5):1117–1125.
UmapathysivamMMLeeMYJonesKL. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide-1 receptor on gastric emptying andglycemia [published online October 2, 2013]. Diabetes. 2013.
8.
MeierJJGoetzeOAnstippJ. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab. 2004;286(4):E621–E625.
9.
PerleyMJKipnisDM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest. 1967;46(12):1954–1962.
10.
NauckMStockmannFEbertRCreutzfeldtW. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52.
11.
VilsbollTKrarupTDeaconCFMadsbadSHolstJJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609–613.
12.
NauckMABaranovORitzelRAMeierJJ. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?Diabetologia. 2013;56(9):1878–1883.
13.
MaratheCSRaynerCKJonesKLHorowitzM. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013;36(5):1396–1405.
14.
DeaneAChapmanMJFraserRJBryantLKBurgstadCNguyenNQ. Mechanisms underlying feed intolerance in the critically ill: implications for treatment. World J Gastroenterol. 2007;13(29):3909–3917.
15.
DeaneAMRaynerCKKeeshanA. The effects of critical illness on intestinal glucose sensing, transporters, and absorption. Crit Care Med. 2014; 42(1):57–65.
16.
DeaneAMHorowitzM. Dysglycaemia in the critically ill - significance and management. Diabetes Obes Metab. 2013;15(9):792–801.
17.
EgiMBellomoRStachowskiE. The interaction of chronic and acute glycemia with mortality in critically ill patients with diabetes. Crit Care Med. 2011;39(1):105–111.
18.
KrinsleyJSEgiMKissA. Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study. Crit Care. 2013;17(2):R37.
19.
DeaneAMChapmanMJFraserRJBurgstadCMBesankoLKHorowitzM. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care. 2009;13(3):R67.
20.
DeaneAMSummersMJZaknicAV. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care. 2011;15(1): R35.
21.
DeaneAMChapmanMJFraserRJ. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med. 2010;38(5):1261–1269.
22.
LeeMYFraserJDChapmanMJ. The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill. Diabetes Care. 2013;36(10):3333–3336.
23.
UmpierrezGEKorytkowskiM. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care. 2013;36(7):2112–2117.
24.
NauckMA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013;36(7):2126–2132.
25.
SciricaBMBhattDLBraunwaldE. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
